Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 3/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25748607 | 0.87 | LMNA (0.36) | HTR1ADRD2HTR2AHTR7NPC1 | |
| SCHEMBL16938128 | 0.86 | SMN1; SMN2 (0.35) | HTR1ADRD2HTR2AHTR7NPC1 | |
| SCHEMBL16722812 | 0.79 | KMT2A (0.46) | SMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL17123489 | 0.79 | TSHR (0.48) | KMT2A | |
| SCHEMBL12391964 | 0.79 | HTR1A (0.30) | HTR1ADRD2HTR2AHTR7NPC1 | |
| SCHEMBL12659419 | 0.78 | RECQL (0.37) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL15961517 | 0.77 | ALDH1A1 (0.45) | HTR1ADRD2HTR2AHTR7NPC1 | |
| SCHEMBL8608901 | 0.77 | TSHR (0.52) | HTR1ADRD2HTR2AHTR7NPC1 | |
| SCHEMBL13610829 | 0.77 | FOLH1 (0.36) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL12750747 | 0.76 | KDM4E (0.32) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364277-A1 | E-SELECTIN TARGETING AGENTS | GLYCOMIMETICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230167150-A1 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | GLYCOMIMETICS, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167149-A1 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | GLYCOMIMETICS, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230144534-A1 | CLEAVABLE TETRAZINE USED IN BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| US-9907860-B2 | Conjugated molecules comprising a peptide derived from the CD4 receptor coupled to an anionic polypeptide for the treatment of AIDS | INSTITUT PASTEUR (FR) | 2018-03-06 | — | — | US | disclosed |
| US-20170326246-A1 | CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO AN ANIONIC POLYPEPTIDE FOR THE TREATMENT OF AIDS | UNIVERSITÉ PARIS-SACLAY (FR) | 2017-11-16 | — | — | US | disclosed |
| US-20170326246-A1 | CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO AN ANIONIC POLYPEPTIDE FOR THE TREATMENT OF AIDS | UNIVERSITÉ PARIS-SACLAY (FR) | 2017-11-16 | — | — | US | disclosed |
| US-9295730-B2 | Conjugated molecules comprising a peptide derived from the CD4 receptor coupled to a polyanion for the treatment of AIDS | INSTITUT PASTEUR (FR) | 2016-03-29 | — | — | US | disclosed |
| US-9295730-B2 | Conjugated molecules comprising a peptide derived from the CD4 receptor coupled to a polyanion for the treatment of AIDS | INSTITUT PASTEUR (FR) | 2016-03-29 | — | — | US | disclosed |
| US-9078928-B2 | Conjugated molecules comprising a peptide derived from the CD4 receptor coupled to a polyanionic polypeptide for the treatment of AIDS | INSTITUT PASTEUR (FR) | 2015-07-14 | — | — | US | disclosed |
| US-8110559-B2 | Hindered ester-based biodegradable linkers for oligonucleotide delivery | ENZON PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20110105412-A1 | CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANION FOR THE TREATMENT OF AIDS | UNIVERSITE PARIS-SUD (FR) | 2011-05-05 | — | — | US | disclosed |
| US-20100279408-A1 | POLYMERIC SHORT INTERFERING RNA CONJUGATES | ENZON PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100234444-A1 | HINDERED ESTER-BASED BIODEGRADABLE LINKERS FOR OLIGONUCLEOTIDE DELIVERY | ENZON PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100233190-A1 | TARGETED POLYMERIC PRODRUGS CONTAINING MULTIFUNCTIONAL LINKERS | ENZON PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100233190-A1 | TARGETED POLYMERIC PRODRUGS CONTAINING MULTIFUNCTIONAL LINKERS | ENZON PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100203066-A1 | POLYMERIC LINKERS CONTAINING PYRIDYL DISULFIDE MOIETIES | ENZON PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20090232833-A1 | POLYALKYLENE OXIDES HAVING HINDERED ESTER-BASED BIODEGRADABLE LINKERS | ENZON PHARMACEUTICALS, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090202573-A1 | POLYMERIC CONJUGATES CONTAINING POSITIVELY-CHARGED MOIETIES | ENZON PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090203706-A1 | LYSINE-BASED POLYMERIC LINKERS | ENZON PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326246-A1 | CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO AN ANIONIC POLYPEPTIDE FOR THE TREATMENT OF AIDS | CD4, CD40LG, HAVCR2 | HTR1A 2511/4885DRD2 2154/4885HTR2A 3446/4885 |
| US-20230167150-A1 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | SIGLEC7, SIGLEC9, CD47 | HTR1A 4197/4885DRD2 4618/4885HTR2A 4387/4885 |
| US-20100233190-A1 | TARGETED POLYMERIC PRODRUGS CONTAINING MULTIFUNCTIONAL LINKERS | PAICS, FCGRT, DNPEP | HTR1A 3755/4885DRD2 2044/4885HTR2A 3530/4885 |
| US-20100279408-A1 | POLYMERIC SHORT INTERFERING RNA CONJUGATES | SNRPE, RNASE1, PHAX | HTR1A 4626/4885DRD2 3528/4885HTR2A 4468/4885 |
| US-20110105412-A1 | CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANION FOR THE TREATMENT OF AIDS | CD4, CD40LG, CD40 | HTR1A 3142/4885DRD2 2521/4885HTR2A 3903/4885 |
| US-20090202573-A1 | POLYMERIC CONJUGATES CONTAINING POSITIVELY-CHARGED MOIETIES | PIGO, PHOSPHO1, PAICS | HTR1A 3993/4885DRD2 2469/4885HTR2A 3594/4885 |
| US-20230144534-A1 | CLEAVABLE TETRAZINE USED IN BIO-ORTHOGONAL DRUG ACTIVATION | KIT, TPSB2, BTD | HTR1A 1323/4885DRD2 2913/4885HTR2A 1007/4885 |
| US-20090232833-A1 | POLYALKYLENE OXIDES HAVING HINDERED ESTER-BASED BIODEGRADABLE LINKERS | CES2, PLOD3, FASN | HTR1A 4319/4885DRD2 4126/4885HTR2A 3200/4885 |
| US-20230167149-A1 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | SIGLEC7, SIGLEC9, ASGR1 | HTR1A 4386/4885DRD2 4554/4885HTR2A 4409/4885 |
| US-20230364277-A1 | E-SELECTIN TARGETING AGENTS | SELE, SELPLG, SELP | HTR1A 3473/4885DRD2 2728/4885HTR2A 3700/4885 |
| US-20100203066-A1 | POLYMERIC LINKERS CONTAINING PYRIDYL DISULFIDE MOIETIES | P4HB, PRDX4, SCLY | HTR1A 3368/4885DRD2 1762/4885HTR2A 3510/4885 |
| US-20090203706-A1 | LYSINE-BASED POLYMERIC LINKERS | KARS1, JMJD6, PHYKPL | HTR1A 3821/4885DRD2 2931/4885HTR2A 4084/4885 |
| US-20100234444-A1 | HINDERED ESTER-BASED BIODEGRADABLE LINKERS FOR OLIGONUCLEOTIDE DELIVERY | VEGFA, DCLRE1B, MSN | HTR1A 4658/4885DRD2 4364/4885HTR2A 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.